Table 3 from A Phase 2 Study of Sotigalimab, a CD40 Agonist Antibody, plus Concurrent Chemoradiation as Neoadjuvant Therapy for Esophageal and Gastroesophageal Junction Cancers
收藏Figshare2025-02-21 更新2026-04-28 收录
下载链接：
https://figshare.com/articles/dataset/Table_3_from_A_Phase_2_Study_of_Sotigalimab_a_CD40_Agonist_Antibody_plus_Concurrent_Chemoradiation_as_Neoadjuvant_Therapy_for_Esophageal_and_Gastroesophageal_Junction_Cancers/28457872
下载链接
链接失效反馈官方服务：
资源简介：
Most common AEs (occurring in ≥10% of subjects) considered related to sotigalimab by the investigator (n = 33)
创建时间：
2025-02-21
